Ardelyx Inc. (NASDAQ: ARDX). ARDX Q4 2025 earnings delivered exceptional results. IBSRELA revenue surged 73% annually. Total company revenues reached $407.3 million. Indeed, the biotech company exceeded expectations with disciplined execution and expanded product adoption. Meanwhile, management provided confident 2026 guidance.
IBSRELA and XPHOZAH Product Performance
So, IBSRELA dominated 2025 with $274.2 million in revenue. This reflects 73% growth versus 2024. Q4 2025 IBSRELA revenue hit $86.6 million. Plus, this represented 61% year-over-year growth. Meanwhile, XPHOZAH contributed $103.6 million for the full year. Indeed, Q4 XPHOZAH revenue was $27.8 million. Notably, total company revenues reached $407.3 million in 2025.
ARDX Q4 2025 Earnings: Financial Results
Recently, full year 2025 net loss was $61.6 million. This compares favorably with prior year performance. Commercial execution improved significantly. So, IBSRELA prescribing depth and breadth expanded. Also, patient engagement with IBS-C population strengthened. Furthermore, prescription pull-through metrics improved substantially. In fact, the company maintained operational discipline throughout 2025.
ARDX Q4 2025 : Key Growth Drivers
IBSRELA adoption accelerated among target healthcare providers. So, increased prescriber engagement drove utilization gains. Plus, patient-first XPHOZAH strategy expanded access. Then, non-Medicare patient populations grew. Meanwhile, development programs for new IBSRELA indication launched. Indeed, next-generation NHE3 inhibitor programs advanced rapidly. As a result, the company built significant momentum entering 2026.
2026 Guidance and Strategic Outlook
Management expects continued momentum in 2026. So, IBSRELA revenue guidance ranges from $410 million to $430 million. This implies at least 50% growth versus 2025. Plus, the company targets IBSRELA reaching $1 billion in annual revenue by 2029. Meanwhile, development programs for new indications progress. Importantly, the company remains well capitalized for current objectives. Indeed, long-term strategy focuses on delivering novel therapies to patients with unmet needs.
ARDX Q4 2025 earnings total company revenue demonstrates expansion of product portfolio beyond IBSRELA.
ARDX Q4 2025 : Key Takeaways
- IBSRELA 2025 revenue: $274.2 million (73% growth)
- Q4 IBSRELA revenue: $86.6 million (61% YoY growth)
- Total 2025 revenues: $407.3 million
- 2026 IBSRELA guidance: $410-430 million (50%+ growth)
For details, see the Ardelyx Q4 2025 earnings press release. Also visit Yahoo Finance or NASDAQ.
Click Here to visit the AlphaStreet website.